do glp 1 cause kidney stones Glucagon-like Peptide Receptor Agonists and Outcomes in the Era of Personalized Medicine: Focus on Albuminuria Ozempic and GLP-1 Drugs: Risk
Description
The good news from clinical trials: most people who maintain tirzepatide treatment continue losing weight, albeit more slowly, even after hitting a plateau
doi: 10.3390/jcm14041042
Understanding these factors will be important for optimizing patient selection and dosing strategies
42.9% of GLP-1 users reported losing less than 20 pounds
